SPOTLIGHT -
Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.
Read More
Dr. Sklar on Immunotherapy Potential in Bladder Cancer
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.
Dr. Sklar on the Role of Nivolumab in Bladder Cancer
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.
Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer
Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
